SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007964
Filing Date
2024-05-13
Accepted
2024-05-13 16:17:29
Documents
91
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cara-20240331x10q.htm   iXBRL 10-Q 1765368
2 EX-31.1 cara-20240331xex31d1.htm EX-31.1 12305
3 EX-31.2 cara-20240331xex31d2.htm EX-31.2 11345
4 EX-32.1 cara-20240331xex32d1.htm EX-32.1 11208
  Complete submission text file 0001558370-24-007964.txt   8563961

Data Files

Seq Description Document Type Size
5 EX-101.SCH cara-20240331.xsd EX-101.SCH 67249
6 EX-101.CAL cara-20240331_cal.xml EX-101.CAL 59128
7 EX-101.DEF cara-20240331_def.xml EX-101.DEF 295507
8 EX-101.LAB cara-20240331_lab.xml EX-101.LAB 529600
9 EX-101.PRE cara-20240331_pre.xml EX-101.PRE 450024
95 EXTRACTED XBRL INSTANCE DOCUMENT cara-20240331x10q_htm.xml XML 1483465
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36279 | Film No.: 24939310
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)